A study on effects of ticagrelor and prasugrel on inflammatory markers, in diabetic patients undergoing percutaneous coronary interventio
- Conditions
- Health Condition 1: E08-E13- Diabetes mellitusHealth Condition 2: I20-I25- Ischemic heart diseases
- Registration Number
- CTRI/2023/06/054193
- Lead Sponsor
- Dr Ankita Panigrahy
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
1.Patients aged between 35 - 70 years of either gender.
2.Diabetic patients , with either stable angina, unstable angina or NSTEMI, with the above mentioned drug therapy and planned for PCI.
3.Patients with Thrombolysis In Myocardial Infarction (TIMI) flow grade 3 after PCI.
1.Patients posted for Coronary bypass surgery.
2.Patients with uncontrolled diabetes
3.History of stroke or transient ischemic attack or intracranial bleeding at any time
4.Patients who had previous cardiac intervention
5.Patients with cardiogenic shock or hypovolemia
6.Left Ventricular Ejection Fraction (LVEF) < 30%
7.Patients with ST segment elevated myocardial infarction
8.Patients with chronic kidney disease stage 3 and beyond
9.Patients requiring reintervention in the study period
10.Need for chronic anti coagulation therapy
11.Patients whose liver function test values are more than 2 times the upper limit of normal
12.History of gastrointestinal bleeding within past 6 months
13.Hypersensitivity to study drugs
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in levels of hsCRP, IL-6,TNF-alpha after 3 months of treatment compared to baseline <br/ ><br>Safety of the drugsTimepoint: baseline, 4 weeks, 12 weeks
- Secondary Outcome Measures
Name Time Method Safety- any incidence of bleeding or stent thrombosisTimepoint: 1 month,4 months